Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1218
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Does Not Support
- Drug
- Salirasib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21847063
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Salirasib | Sensitivity | false |